ClinicalTrials.gg
RecruitingNCT05586282Updated Oct 15, 2024

Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure

An observational study in Cardiogenic Shock, Postresuscitation Disease and Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
380
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.

Planned enrollment
12th of 37
380 · median 150
Started
2023
with 5 others
Observational
37 of 62
10 open now
Primary completion
2026-03
later than 3 of 20 live
Registered
41st of 62
by date
Lead sponsor
7 of 62
Assistance Publique - Hôpitaux de Paris

Among the 62 studies in Shock, Cardiogenic with a site in France, this one is the 12th largest by planned enrollment of the 37 observational ones that give a count, is one of 6 that started in 2023, is one of 37 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 41st registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Shock, Cardiogenic with a site in France, or all of them as a file.
02

Study summary

  • Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome.
  • Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans
Read the detailed description

Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality [1,2]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure [1,3]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock [4-7] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure [8-10]. However, the determinants of vascular leakage remain poorly understood in humans.

The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.

03

Conditions studied

  • Cardiogenic Shock
  • Postresuscitation Disease
  • Septic Shock
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. from patient or a legal representative/family member/close relative. The patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
  2. Affiliation to social security (AME excluded)
  3. Patient with one of the circulatory failures described below:

    • septic shock
    • cardiogenic shock
    • post-resuscitation syndrome
    • Cardiogenic shock:

      • Need for a catecholamine support to maintain mean arterial pressure>65 mmHg, AND
      • Cardiac index \<2 L/min/m2 or (LVEF)\<35%, AND
      • Lactate >2.0 mmol/l
    • Post-resuscitation syndrome:

      • Cardiac arrest (absence of spontaneous respiration, palpable heartbeat, and responsiveness to stimuli> 1 min) with a compatible (asystole/pulseless electrical activity/ventricular tachycardia), AND
      • Need for a catecholamine support to maintain mean arterial pressure>65 mmHg, AND
      • Lactate >2.0 mmol/l
    • Septic shock:

      • Suspected or proven bacterial infection
      • Need for a vasopressor support to maintain mean arterial pressure>65 mmHg
      • Lactate >2.0 mmol/l
      • Cardiac index>3L/min/m2 or LVEF>40%

Exclusion criteria

Exclusion Criteria:

  1. Onset of shock (catecholamine infusion) >12 hours prior to inclusion
  2. Age \<18 year old
  3. Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
380 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with a circulatory failure

    All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.

06

What researchers measure

Primary outcomes

  1. Fluid balance from Day 0 to day 3

    (ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,...)

    Time frame: Between Day 0 and Day 3

Secondary outcomes

  1. Fluid balance

    (ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,...)

    Time frame: Day 1, Day 3, Day 7, Day 14

  2. Extra-vascular lung water index

    Extra-vascular lung water index (EVLWi, ml/kg) and pulmonary vascular permeability index measured by transpulmonary thermodilution at corresponding time-points

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  3. Serum albuminemia

    g/L

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  4. Serum lactatemia

    mmoles/L

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  5. Arterial PaO2

    (mmHg)

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  6. Circulating cytokine inflammatory profile IL-33

    (pg/ml)

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  7. Circulating cytokine inflammatory profile TNF-alpha

    (pg/ml)

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  8. Circulating cytokine inflammatory profile IL-6

    (pg/ml)

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  9. Circulating cytokine inflammatory profile IL-1

    (pg/ml)

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  10. SOFA score

    Association between circulating candidate proteins, the immune-inflammatory profile of the patients and SOFA score

    Time frame: Day 0, Day 1, Day 3, Day 7, Day 14

  11. Catecholamine-free days

    Number of days alive without receiving any catecholamine

    Time frame: Day 0 to Day 7, Day 30

  12. Ventilatory-free days

    Number of days alive without receiving any machenical ventilation, invasive or non-invasive

    Time frame: Day 0 to Day 7, Day 30

  13. Renal replacement therapy-free

    Number of days alive without receiving any renal replacement therapy

    Time frame: Day 0 to Day 7, Day 30

  14. Mortality

    Time frame: Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2026, 36 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 36 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 19, 2022
StartActual
Mar 20, 2023
Primary completionEst.
Mar 2026
CompletionEst.
Apr 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05586282
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Mar 20, 2023
Primary completion
Mar 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Nicolas BRECHOT, MD, PhD
Contact
nicolas.brechot@aphp.fr
+331 56 09 23 42

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion